




The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Agios Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 361%, being 98% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	337,329
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	52,888
Liabilities, Non-Current	0
Other Assets	59,516
Other Compr. Net Income	-261
Other Expenses	0
Other Liabilities	0
Other Net Income	968
Other Revenues	59,119
Property and Equipment	23,220
Research and Development	141,827
Selling, General and Administrative Expense	35,992

Output Variable	Value in 1000 USD
Assets	420,065
Liabilities	52,888
Expenses	177,819
Revenues	59,119
Stockholders Equity	367,177
Net Income	-117,732
Comprehensive Net Income	-117,862
BaseVar	355,560
ECR before Limited Liability	289%
Economic Capital Ratio	361%